4
FDA-approved indications
30,000+
patients treated through January 2024
$509M
annual net revenues (2023)
$223M
annual R&D investments (2023)
4
ongoing phase 3 trials
press releases
October 30, 2024
Novocure Appoints Christoph Brackmann as Chief Financial Officer
October 30, 2024
Novocure Reports Third Quarter 2024 Financial Results
events and presentations
Sep 4, 2024
Wells Fargo Healthcare Conference
Jul 25, 2024
Novocure Q2 2024 Earnings Conference Call
view all
latest filings
view all
reports
See our online annual reports and more.
2023
annual materials
2022
annual materials
2021
annual materials
contact us
investorinfo@novocure.com
610-723-7427
sign up for email alerts
To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.
"*" indicates required fields